Figure 1 Mechanisms of action of immunotherapy modalities

Slides:

Advertisements

Similar presentations

Activation of T Lymphocytes

Advertisements

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll Cancer Cell

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Tumor Immunity: Exploring the Role of a Checkpoint

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Adverse Renal Effects of Immune Checkpoint Inhibitors:

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Radiation-induced effects on tumour cells

Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 3 Altered adaptive immune functions after sepsis

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Four nodes to target when inducing anti-tumour immunity

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Figure 1 Chimeric antigen receptor (CAR) structures

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Figure 5 Classification of immunotherapies

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Co-Receptors: Function

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 CAR-T-cell design

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 6 Combination therapy for HCC

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Urol. doi: /nrurol

Figure 4 Macrophage-targeting antitumour treatment approaches

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Structure of different types of T-cell-engaging antibodies

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of CTLA4 and PD1 in T cell activation

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Site of action of checkpoint inhibitors and agonists being

Mechanisms of immune escape in the tumor microenvironment.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Dendritic cells: regulators of hepatic immunity or tolerance?

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit Kristen E. Pauken,

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Cell-mediated immunity Regulation of the immune response

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Figure 4 Molecular signalling and immunological

General overview of innate and adaptive immune responses to and regulation of black yeasts. General overview of innate and adaptive immune responses to.

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.

Presentation transcript:

Figure 1 Mechanisms of action of immunotherapy modalities Figure 1 | Mechanisms of action of immunotherapy modalities. Native T cells can recognize tumour-specific antigens in an MHC-dependent manner. The T cells also require co-stimulation for activation. Upon antigen recognition, without co-stimulatory signal, or with the stimulation of inhibitory molecules, such as through the PD-1–PD-L1 axis, the T cells can be induced to anergy or become exhausted. Immune-checkpoint inhibitors can block the inhibitory signal of T cells to avert T cells from anergy. BiTE® antibodies bring T cells and malignant cells into close proximity through dual antigen binding, and can induce T-cell activation without co-stimulatory signals. T-cells can also be engineered to express CARs to recognize cell-surface molecules independent of MHC. Later-generation CARs have both TCR and co-stimulatory signalling components, thereby activating the T cells without additional co-stimulatory signal. Abbreviations: ADC, antibody–drug conjugate; BiTE®, bispecific T-cell engager antibody; CAR, chimeric antigen receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; mAb, monoclonal antibody; MHC, major histocompatibility complex; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; TCR, T-cell receptor. Batlevi, C. L. et al. (2015) Novel immunotherapies in lymphoid malignancies Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.187